BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Frost & Sullivan Lauds Pfenex Inc. for Developing a Protein Expression Platform that Delivers Unparalleled Success and Speed


6/5/2012 12:19:47 PM

SAN DIEGO, June 5, 2012 /PRNewswire/ -- Based on its comprehensive TEAM Research rigorous 10 step evaluation methodology, Frost & Sullivan has awarded Pfenex Inc. with the 2012 North American Enabling Technology Award in Microbial Expression Technology. Frost & Sullivan industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

In order to be selected for the prestigious Enabling Technology Award, the following criteria were used to benchmark Pfenex's performance against its key competitors:

  • Enables Creation of New Products
  • Enhances Current Products
  • Enables New Applications
  • Potential for Market Acceptance
  • Delivery of Technology to Market

Overcoming historic bottleneck issues in biopharmaceutical development, Pfenex Inc. through its Pseudomonas fluorescens-based platform, Pfenex Expression Technology, offers a novel microbial expression technology that has demonstrated its ability to rapidly and repeatedly produce difficult-to-express proteins.

"Their speed and success rate is unparalleled in this market," says Frost & Sullivan Industry Analyst Sangeetha Prabakar. "With rapid development, high yield and uncompromised quality, this platform has been used for the production of not only innovator biologics, but also biosimilars and reagent proteins. This technology platform has enabled several developers to take their products towards clinical development, which otherwise would have been abandoned due to production challenges."

"On behalf of the entire Pfenex team and investors we are honored to receive this prestigious award from Frost & Sullivan," said Dr. Bertrand C. Liang, Chief Executive Officer of Pfenex, "Pfenex has developed a platform that transcends legacy protein production technologies, and this award serves as validation of that effort."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

SOURCE Pfenex Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES